MedPath

BioLab Holdings Advances Venous Leg Ulcer Treatment with IRB Approval for Membrane Wrap Trial

• BioLab Holdings has received IRB approval for a multi-center randomized control trial to evaluate their Membrane Wrap product's efficacy in treating venous leg ulcers in elderly patients.

• The Phoenix-based company will collaborate with 18 clinical sites to conduct the trial, with enrollment expected to begin following site agreement completion in the next 2-8 weeks.

• The study marks BioLab's first randomized control trial for their human amniotic membrane-based wound care product, demonstrating their commitment to evidence-based treatment validation.

BioLab Holdings, Inc., a Phoenix-based medical manufacturer, has secured Institutional Review Board (IRB) approval for a landmark clinical trial evaluating their innovative wound care product, Membrane Wrap™, in the treatment of venous leg ulcers.
The multi-center, prospective, randomized trial will assess the efficacy of the company's human amniotic membrane-based skin substitute specifically targeting elderly patients with venous leg ulcers. The study protocol was developed in partnership with MCRA, a Washington D.C.-based organization.
Dr. Marshall Medley, Chief Medical Officer at BioLab, expressed enthusiasm about the trial's potential impact: "We are very excited to be involved in this trial to ensure our Membrane Wrap's efficacy. This is the first of several randomized control trials we will be involved in, and we look forward to getting our products to even more patients in need of wound care."

Trial Implementation and Timeline

The study will span across 18 carefully vetted clinical sites. Site agreements are currently being distributed, with the enrollment phase expected to commence within the next two to eight weeks following agreement completion.

Product Innovation and Support Services

Membrane Wrap™ is part of BioLab's comprehensive wound care portfolio, which includes variations such as Membrane Wrap Lite™, Tri-Membrane Wrap™, and Membrane Wrap - Hydro™. These products utilize human tissue allograft derived from amniotic membrane, serving as wound protectant coverings while maintaining the tissue's natural properties through minimal manipulation.
BioLab distinguishes itself in the wound care market through its holistic approach to provider support. The company offers comprehensive services including:
  • Pre-application support with product protocols and timeline guidance
  • Application training and product inservice education
  • Benefits and insurance verification assistance
  • Billing training and support
  • Post-application support including proof-of-concept guidance
  • Denied claims assistance and charity care services
This integrated approach ensures healthcare providers receive complete support throughout the wound care treatment process, from initial product application to follow-up care.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

PathMaker's MyoRegulator Device for ALS Receives IRB Approval for DoD-Funded Clinical Trial

PathMaker Neurosystems has received IRB approval to begin enrollments in the CALM study, a clinical trial of the MyoRegulator device for ALS.
The CALM study, funded by the U.S. Department of Defense, will assess the safety and feasibility of MyoRegulator in ALS patients.

BioStem Technologies Initiates Pivotal Trial of Vendaje® for Diabetic Foot Ulcers

BioStem Technologies has launched a clinical trial (BR-AM-DFU) to evaluate Vendaje® for treating non-healing diabetic foot ulcers (DFUs).
The multicenter, randomized, controlled study will enroll 60 patients across 12 U.S. sites to assess Vendaje®'s efficacy versus standard care.

NanoVibronix's UroShield Completes Pilot Phase for UTI Prevention

NanoVibronix has successfully completed the pilot phase of a randomized controlled trial for UroShield, a device designed to prevent catheter-associated urinary tract infections (UTIs).
The pilot phase, conducted at the University of Michigan, focused on refining recruitment strategies and assessing data collection tools for the full study.

Merakris Therapeutics Opens Enrollment for Phase 2 Trial of Dermacyte Liquid for Venous Leg Ulcers

Merakris Therapeutics has initiated enrollment for Part 2 of its Phase 2 clinical trial evaluating Dermacyte Amniotic Wound Care Liquid for venous leg ulcers.
The study is a randomized, double-blind, placebo-controlled trial across 10 U.S. medical centers, assessing the subcutaneous injection in up to 50 patients.

BioAdaptives' Zeranovia Receives IRB Approval for Human Clinical Trial in Weight Management

BioAdaptives Inc. has secured Institutional Review Board (IRB) approval to commence a human clinical trial for its weight management product, Zeranovia™.
The initial phase of the trial, to be conducted in Las Vegas, Nevada, will focus on confirming dosing and identifying potential side effects.

BioAdaptives' Zeranovia Receives IRB Approval for Weight Management Clinical Trial

BioAdaptives Inc. has secured IRB approval to commence human clinical trials for Zeranovia, a weight management product, in Las Vegas, Nevada.
The initial phase of the trial will focus on confirming the appropriate dosage and monitoring for any potential side effects in participants.

BioAdaptives' Zeranovia Receives IRB Approval for Human Clinical Trial in Weight Management

BioAdaptives Inc. has secured IRB approval to begin a human clinical trial for Zeranovia, its weight management product, marking a significant step in its development.
The initial phase of the trial will focus on confirming appropriate dosing and identifying any potential new side effects associated with Zeranovia.

Medtronic's Prevail Drug-Coated Balloon Receives FDA IDE Approval for Pivotal Trial

Medtronic has received FDA approval for an IDE to begin a pivotal clinical trial of its Prevail drug-coated balloon (DCB).
The trial will evaluate the safety and efficacy of Prevail DCB for in-stent restenosis (ISR) and de novo small vessel disease.

BioStem Technologies' BioREtain Shows Promise in Healing Diabetic Foot Ulcers

A retrospective study published in the *International Wound Journal* highlights the clinical efficacy of BioREtain-processed placental membranes (RE-AC) in treating complex diabetic foot ulcers (DFUs).
Patients treated with RE-AC had an 8.53% higher probability of complete wound closure compared to the standard of care (SOC) group after 12 weeks.

BioLab Holdings Initiates Clinical Trials for Amniotic Membrane Tissue in Venous Leg Ulcer Treatment

BioLab Holdings has commenced clinical trials for its amniotic membrane tissue, aiming to improve the treatment of difficult-to-heal venous leg ulcers.
The FDA-approved study will assess the effectiveness of BioLab Sciences' membrane in managing partial- or full-thickness venous leg ulcers in patients aged 50-85.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy